Reevaluation of Expression of SALL4 and PAX8 in Carcinomas from Various Organs.
Myra Wilkerson, Jianhui Shi, Haiyan Liu, Jeffrey W Prichard, Fan Lin. Geisinger Medical Center, Danville, PA
Background: SALL4 and PAX8 are two recently described useful immunohistochemical markers. SALL4 is a sensitive and specific maker for germ cell tumors, including seminoma, embryonal carcinoma, and yolk sac tumor. PAX8 is a sensitive marker for thyroid carcinomas, ovarian serous carcinoma and renal cell carcinomas. However, the published data were limited and inconsistent. In this study, we attempted to re-evaluate the expression of SALL4 and PAX8 in a large series of carcinomas from various organs using a single immunostaining system (Ventana XT).
Design: Immunohistochemical evaluation of the expression of SALL4 (Cat. No CM384C; Biocare Medical) and PAX8 (Cat. No. CP379AK; Biocare Medical) on 872 cases of carcinomas from various organs using tissue mircroarray sections was performed. The staining intensity and the distribution were recorded.
Results: The positive staining results (%) and the total number of cases for each entity (N) are summarized in Table 1. Twenty-two cases of intratubular germ cell neoplasia (ITGCN) were also positive for SALL4. One case of carcinoma from each of the colon, esophagus, endocervix and ovary was positive for SALL4. Both SALL4 and PAX8 are negative for lung ADC (N=50), lung SCC (N=49), medullary thyroid CA (N=10), gastric ADC (N=21), Pancreatic ADC (N=50), urothelial CA (N=40), prostatic ADC (N=100), cholangiocarcinoma (N=11), breast ductal CA (N=110) and lobular CA (N=31), hepatocellular CA (N=18) and adrenal cortical neoplasm (N=24).
|Tumor||SALL4 (%)||PAX8 (%)|
|Embryonal CA (N=24)||100||0|
|Yolk sac tumor (N=12)||100||0|
|Papillary thyroid CA (PTC, N=45)||0||93|
|Follicular thyroid CA (FTC, N=36)||0||100|
|Anaplastic thyroid (ATC, N=5)||0||40|
|Clear cell RCC (N=36)||0||97|
|Papillary RCC (N=25)||0||100|
|Colonic ADC (N=38)||3||3|
|Esophageal ADC (N=30)||3||0|
|Endocervical ADC (N=17)||6||53|
|Ovarian serous CA (N=15)||6||100|
|Pancreatic endocrine neoplasm (PEN, N=15)||0||33|